Aileron Therapeutics, INC

Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an increase in authorized common stock and ratified auditor appointment.

Rein Therapeutics announced the pricing of a $50 million underwritten public offering of common stock, with net proceeds expected to fund its Phase 2 clinical trial for LTI-03.

Rein Therapeutics, Inc. announced the immediate resignation of Dr. Manuel C. Alves Aivado from its Board of Directors, citing no disagreements with company operations.

Rein Therapeutics, Inc. has secured a $2.5 million unsecured promissory note from Funicular Funds, LP, with a 20% original issue discount and a maturity date by June 30, 2026, or earlier upon a significant future capital raise.

Rein Therapeutics, Inc. has terminated its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with Yorkville, having drawn $3 million under the PPA with no penalties.

Rein Therapeutics announced FDA clearance to resume its U.S. Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, with enrollment expected to restart in late 2025 or early 2026.

Rein Therapeutics reports progress on LTI-03 Phase 2 trial and significant capital raise, aiming to extend runway into Q1 2028.

Rein Therapeutics announced the FDA lifted the clinical hold on its lead IPF candidate LTI-03, but disclosed substantial doubt about its ability to continue as a going concern past December 2025 without additional funding.

Rein Therapeutics reported a clinical hold on its lead LTI-03 trial, raised capital through new agreements, and disclosed substantial doubt about its ability to continue as a going concern.

Rein Therapeutics reports a net loss of $5.5 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Aileron Therapeutics announced positive topline data from its Phase 1b clinical trial of LTI-03 for IPF, while also expressing substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Aileron Therapeutics reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and a strategic shift in resource allocation.

Rein Therapeutics, Inc. files an amendment to its 2025 10-K report, primarily to include previously omitted information regarding directors, executive officers, and corporate governance.

Rein Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses and raised substantial doubt about its ability to continue as a going concern, leading to an indefinite pause in LTI-01 and preclinical programs.

Rein Therapeutics files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

Rein Therapeutics reports its 10-K filing, highlighting positive clinical data for LTI-03 but also raising concerns about its ability to continue as a going concern due to insufficient funds.

Aileron Therapeutics has filed an amendment to its annual report to include information previously omitted regarding directors, executive compensation, and corporate governance.

Aileron Therapeutics has completed its acquisition of Lung Therapeutics, shifting its focus to orphan pulmonary and fibrosis indications and advancing clinical programs for LTI-03 and LTI-01.

Director Josef H. von Rickenbach acquired 47,060 shares of Rein Therapeutics, Inc. common stock through open market purchases.

Rein Therapeutics, Inc. reports that President and CEO James Brian Windsor acquired shares in a follow-on offering and was granted stock options.

Voss Capital and affiliated entities increased their beneficial ownership in Rein Therapeutics, Inc. by acquiring 104,183 shares of common stock.

Voss Capital, a 10% owner and director, significantly expanded its beneficial ownership in Rein Therapeutics, Inc. through recent common stock purchases.

Rein Therapeutics, Inc. Director Manuel Aivado was granted 17,500 stock options with an exercise price of $1.55, vesting fully by July 2026.

Rein Therapeutics, Inc. Director Josef H. von Rickenbach was granted 17,500 stock options with an exercise price of $1.55 per share, vesting by July 2026.

Rein Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 20, 2026, to address key corporate matters including director elections and a significant increase in authorized shares.

A company has reduced its quorum requirement for its annual stockholder meeting from a majority to 40% after failing to achieve a quorum at its initially scheduled meeting.

Rein Therapeutics announced the adjournment of its 2025 annual meeting of stockholders to July 23, 2025, due to a failure to achieve a quorum, urging stockholders to vote on pending proposals.

Rein Therapeutics will hold its annual meeting on June 24, 2025, seeking stockholder approval for the election of a Class II director and executive compensation.

Rein Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on June 24, 2025, to vote on director election and executive compensation.

Aileron Therapeutics announces its annual stockholder meeting to be held on August 20, 2024, featuring proposals including the election of directors and ratification of the company's accounting firm.

Rein Therapeutics, Inc. has filed a registration statement for a proposed public offering of 30,000,000 shares of common stock to fund clinical development and operations.

Rein Therapeutics entered into a $15 million standby equity purchase agreement with Yorkville to fund clinical development, while facing a U.S. FDA clinical hold on its lead LTI-03 trial.

Voss Capital and affiliated entities report beneficial ownership of 6.6% of Rein Therapeutics' common stock as of June 30, 2026.

A group of investment funds managed by Bios Capital Management has reported a 9.99% beneficial ownership stake in Rein Therapeutics, Inc.

Lynwood Capital Management and associated entities have reported a 6.1% beneficial ownership stake in Rein Therapeutics, Inc. following a recent equity offering.

Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma-Weaver have filed a Schedule 13G reporting a 6.7% beneficial ownership stake in Rein Therapeutics, Inc.

Laurence W. Lytton has reported beneficial ownership of 4,500,000 shares, representing 5.8% of the common stock of Rein Therapeutics, Inc.

Voss Capital and its affiliates have reported an aggregate beneficial ownership of 11.3% in Rein Therapeutics, Inc. common stock.